QuidelOrtho (US:QDEL) Prnewswire·2024-06-10 09:45Group 1 - The complaint against QuidelOrtho Corporation alleges that the company made materially false and misleading statements regarding its COVID-19 test sales and inventory levels [1] - It is claimed that QuidelOrtho sold more COVID-19 tests than its distributors and pharmacy chain customers could resell, leading to excess inventory throughout the supply chain [1] - The complaint suggests that these issues resulted in distributors and pharmacy chain customers significantly reducing their COVID-19 test orders, impacting the company's financial outlook [1] Group 2 - The class period for the allegations is defined as February 18, 2022, to April 1, 2024, during which shareholders are encouraged to register for the class action [5] - Shareholders who purchased shares of QuidelOrtho during the class period are invited to contact the Gross Law Firm regarding potential lead plaintiff appointment [4][5] - The deadline for shareholders to seek lead plaintiff status is June 11, 2024, and there is no cost or obligation to participate in the case [5]